Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.
about
Warfarin initiation nomograms for venous thromboembolismOutpatient versus inpatient treatment for acute pulmonary embolismWarfarin initiation nomograms for venous thromboembolismOptimal loading dose of warfarin for the initiation of oral anticoagulationEvidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesGuidance for the practical management of warfarin therapy in the treatment of venous thromboembolismEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinClinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiationOutpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management.Integration of genetic, clinical, and INR data to refine warfarin dosing.Optimal loading dose for the initiation of warfarin: a systematic reviewLaboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Can you prevent adverse drug events after hospital discharge?Guidelines on oral anticoagulation (warfarin): third edition--2005 update.Warfarin for refractory chronic cluster headache: a randomized pilot study.Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials.Initiating warfarin therapy: 5 mg versus 10 mg.Genetic-based dosing in orthopedic patients beginning warfarin therapy.Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin.Treatment of deep vein thrombosis: what factors determine appropriate treatment?Practical challenges in the management of oral anticoagulation.The pharmacogenetics of coumarin therapy.Factors influencing warfarin response in hospitalized patients.Managing oral anticoagulation requires expert experience and clinical evidence.The risks of warfarin use in the elderly.Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centreA systems approach to designing effective clinical trials using simulations.Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarinManaging oral anticoagulation therapy: improving clinical outcomes. A review.Warfarin Dosing and Time Required to Reach Therapeutic International Normalized Ratio in Patients with Hypercoagulable Conditions.Review article: Coagulation cascade and therapeutics update: relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anticoagulants.Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.Prediction of warfarin dose: why, when and how?Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism.Variation in warfarin prescribing and dosing in the UK: a national survey of anticoagulation clinics.Warfarin: its highs and lows.Management of Pulmonary Embolism: 2010 State-of-the-Art Update.[Anticoagulation in the elderly].
P2860
Q24186324-03416CC3-CE5E-47A4-AA48-B68026005DBDQ24187901-9F62FC45-60D4-4A49-84AC-28CBA4DE006FQ24201274-56E274D7-2DB2-43B7-8234-A551447423EBQ24202077-5D1343AC-A74B-40A4-BEFB-A4C694D39434Q24632951-C23D1438-F120-4CE7-9104-FDD2538758CCQ28066527-C78C2C95-2EFF-4A0F-AD65-692858E8EA98Q28276514-196A15ED-E678-4C54-9ABC-49CD174655E3Q31042226-91775573-9126-490E-854C-E50560561227Q33311569-178ADC0E-60F0-4312-BCA3-9B970C3EE75BQ33550741-80771D37-FDBA-46BB-83E8-A2A3591C759AQ33559159-A6C83EAE-6FE9-4816-892D-66574861583CQ34061511-EE7793AE-0261-4EAB-AFD9-3DF5CA803401Q34252907-A31CDDB9-829C-43A1-9E91-2DB7D8E84F48Q34461601-D68B54B3-31CE-4132-9F5F-2863B9C99004Q34484090-42E94CDA-FAD0-4537-BF2A-0A2EBA78951FQ34660438-376C4840-D757-4C6C-8378-79DD8137AD68Q35870028-01A34A33-F611-42D2-9EDD-52DF129427E3Q35937712-58380549-EB28-45EC-A11F-04307B6D56B6Q35989429-9131A530-C864-414C-8674-64C498AA0E93Q36015458-C93EB250-AA15-4560-8791-C22DE80AB883Q36063745-448B2B0B-D550-4AD0-961B-163E8C7DCEC9Q36123496-E831E645-49D7-44B1-8A41-D290278F0330Q36192806-B1190F81-3747-4FBD-9DA1-4E00DA82E431Q36346124-AA282C8E-7219-40B9-898B-4DB3728F36F1Q36395279-4B5C17D4-23B8-48C4-8296-847B50477299Q36446904-58E26133-DE0D-4291-97CD-BFDA9549D645Q36527615-E1EC08A7-509E-4E8E-BBF3-5230D910F027Q37106741-21FF82DD-8E1C-4FA2-B5D7-6E29FDCC1CE3Q37160420-C06CF74D-D28D-4843-B24A-F980FDBF34D9Q37366805-356D81C6-9ECC-4887-95D0-958F0D21EF43Q37548255-22E038CD-465F-4A58-84AD-A19F02C04B33Q37578743-44F462B2-DFAB-493C-952B-9B08F111A326Q37933420-5F55E691-4B3E-46EB-BBB1-C2ADC02CB92EQ37989489-BACBCE59-2FFC-4B0D-9D61-81D1508D620EQ38274487-6E658CFB-645B-44CE-8D92-0CE8ECBA1BDDQ39326279-0880D169-C9DB-4C8B-83AA-6DC5B09C2B27Q40880691-603B78E5-EBEF-4C1F-9DA9-5009522EDA51Q41942901-1E96FB9C-9523-4C1A-82C2-C4B827C59B98Q42907039-C195E953-9901-4F9A-9165-4165A8CD8631Q42922806-8F51A78C-CDF8-42C7-B112-7666B336D6FF
P2860
Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@ast
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@en
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@nl
type
label
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@ast
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@en
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@nl
prefLabel
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@ast
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@en
Comparison of 10-mg and 5-mg w ...... ouble-blind, controlled trial.
@nl
P2093
P1476
Comparison of 10-mg and 5-mg w ...... double-blind, controlled trial
@en
P2093
Beverly Morrow
David R Anderson
Gertrude Kells
Judy Kovacs
Marc Rodger
Michael J Kovacs
Philip S Wells
P304
P356
10.7326/0003-4819-138-9-200305060-00007
P407
P577
2003-05-01T00:00:00Z